上海心瑋醫療科技股份有限公司 章 程 （於2026年1月16日的臨時股東大會審閱通過） | 第一章 | 總則 | 1 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 3 | | 第三章 | 股份 | 4 | | 第一節 | 股份發行 | 4 | | 第二節 | 股份增減和回購 | 9 | | 第三節 | 股份轉讓 | 13 | | 第四節 | 購買公司股份的財務資助 | 14 | | 第五節 | 股票和股東名冊 | 16 | | 第四章 | 股東和股東會 | 20 | | 第一節 | 股東 | 20 | | 第二節 | 股東會的一般規定 | 26 | | 第三節 | 股東會的召集 | 28 | | 第四節 | 股東會的提案與通知 | 30 | | 第五節 | 股東會的召開 | 33 | | 第六節 | 股東會的表決和決議 | 38 | | 第七節 | 類別股東表決的特別程序 | 43 | | 第五章 | 董事會 | 46 | | 第一節 | 董事 | 46 | | 第二節 | 董事會 | 49 | | 第三節 | 董事會專門委員會 | 54 | | 第六章 | 高級管理人員 | ...

Group 1 - The article reports on share buybacks conducted by various companies on January 23, 2026, with a total of 36 companies participating in the buyback program [1] - The largest buyback amount was by Sunny Optical Technology (02382), which repurchased 850,000 shares for a total of 54.15 million yuan [1] - Other notable buybacks include China Resources Gas (01193) with 1.05 million shares repurchased for 22.80 million yuan and Country Garden Services (06098) with 2.10 million shares for 13.17 million yuan [1] Group 2 - The cumulative buyback numbers for the year show that Sunny Optical Technology has repurchased a total of 12.72 million shares, representing 1.162% of its total share capital [2] - China Resources Gas has repurchased 404.44 million shares, accounting for 0.175% of its total share capital [2] - Kuaishou-W (01024) repurchased 1.24 million shares, which is 0.450% of its total share capital [2] Group 3 - Other companies with significant buybacks include Yum China (09987), which repurchased 20,100 shares for 7.69 million yuan, representing 5.220% of its total share capital [2] - The buyback activity reflects a trend among companies to return capital to shareholders amid market conditions [1][2] - The data indicates a diverse range of industries participating in the buyback program, from technology to healthcare and consumer services [1][3]

Group 1 - The company, 心玮医疗-B (06609), announced a share buyback plan [1] - The company will spend HKD 2.2582 million to repurchase 40,000 shares [1] - The buyback is scheduled for January 23, 2026 [1]

Group 1 - Company X announced a share buyback of 40,000 shares at a cost of HKD 2.2582 million [1] - The buyback price ranged from HKD 54.5 to HKD 57.45 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期： 2026年1月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 第 2 頁 共 7 頁 v 1.3.0 FF305 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 ...

Core Viewpoint - The company, 心玮医疗-B (06609), announced a share buyback plan, indicating a strategic move to enhance shareholder value through the repurchase of shares [1] Group 1 - The company will spend HKD 2.243 million to repurchase 40,000 shares [1]

Group 1 - The company, Heartway Medical-B (06609.HK), announced a share buyback on January 22, 2026, spending HKD 2.243 million to repurchase 40,000 shares [1] - The buyback price ranged from HKD 53.8 to HKD 57.7 per share [1]

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2026年1月21日 | | ...

Core Viewpoint - The profitability of Xinwei Medical is becoming increasingly clear, with a significant growth forecast for 2025, marking its entry into the profit zone, alongside the acceptance of its innovative self-expanding intracranial drug-eluting stent application by the National Medical Products Administration [1][4]. Financial Performance - Xinwei Medical's 2025 revenue is projected to be between 400 million to 410 million yuan, representing an approximate 44% increase from 278 million yuan in 2024 [6]. - The company expects a pre-tax profit of 80 million yuan, a substantial turnaround from a pre-tax net loss of 12 million yuan in 2024, indicating an increase of nearly 800% [6]. Product Development and Market Position - The growth is primarily driven by the collaborative expansion of the entire product line, particularly in the ischemic stroke sector, where new products and technologies have led to a steady increase in market share [7]. - The sales volume of large-caliber aspiration catheters has seen a 60% year-on-year increase in the first half of 2025, with expectations of over 200% growth for the year [8]. - The "Great Wall" intracranial stent has achieved rapid commercial sales, covering 200 new cooperative hospitals in the first half of the year, significantly boosting the sales of related products [8]. Cost Management and Operational Efficiency - Xinwei Medical's overall gross margin rose to nearly 70% in the first half of 2025, while the sales and management expense ratio decreased by 8 percentage points to 37%, showcasing effective cost control [9]. - The financial characteristics of revenue growth, profit increase, and cost reduction indicate a shift from reliance on financing cash flow to a self-sustaining growth model [9]. Innovation and Long-term Strategy - The acceptance of the self-expanding intracranial drug-eluting stent application highlights the company's leading position in innovation, addressing critical treatment needs in the market [12]. - Xinwei Medical has developed a comprehensive product pipeline for stroke treatment and prevention, including devices for thrombectomy, aneurysm, and stenosis, with several products receiving "priority review" status [12]. - The company is also exploring advanced fields such as the interventional brain-machine interface project, which is expected to begin clinical trials by the end of 2026, potentially expanding its growth horizons [12]. Conclusion - Xinwei Medical's solid profitability, comprehensive product pipeline, leading innovation capabilities, and clear ecological layout constitute its core competitive advantages, gradually gaining market recognition for its investment value [14]. - Short-term growth will be supported by full product line expansion and cost control optimization, while long-term prospects are bolstered by innovative products and strategic positioning in emerging fields [14].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 重新提交 公司名稱： 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期： 2026年1月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | ...